23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases
News Jan 29, 2009
23andMe, Inc. and mondoBIOTECH AG, a Swiss research company dedicated to the development of treatments for rare diseases, have announced at the World Economic Forum in Davos, Switzerland, that they are collaborating to advance research of rare diseases.
The announcement marks the return of the companies to the World Economic Forum, where they both were recognized as Technology Pioneers in 2008.
23andMe and mondoBIOTECH will work together to facilitate research of the genetic bases of rare and potentially fatal diseases, such as Pulmonary Arterial Hypertension, Sarcoidosis, and Pulmonary Fibrosis, the genetics of which are poorly understood. mondoBIOTECH will identify individuals suffering from certain rare diseases and sponsor their enrollment in the 23andMe Personal Genome Service™.
Researchers then will be able to study the genetic information collected, along with any phenotypic information provided, in clinical trials, to understand potential causes of these diseases. 23andMe will coordinate genome-wide association studies for mondoBIOTECH affiliates using its research infrastructure and bioinformatics expertise.
"We are eager to take an active role in advancing research of rare genetic disorders," said Linda Avey, co-founder of 23andMe. "By partnering with our colleagues at mondoBIOTECH, a company acutely focused in this area, we'll be able to leverage the genetics and bioinformatics expertise of our science team toward better understanding of these often devastating conditions."
"For years, we have been working on behalf of neglected and underserved disease communities to help improve the lives of people with rare and fatal diseases," said Fabio Cavalli, Chief Executive Officer of mondoBIOTECH. "When we met the founders of 23andMe last year at Davos and saw what they were doing with genetics, we knew that a collaboration between the two companies could go a long way towards understanding the causes of the diseases we have been researching."
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018